Hokkaido University – BioｰEurope 2026
2026.10.16
Hokkaido University will participate in BIO-Europe 2026, one of the world's leading biotechnology and biopharmaceutical partnering events, to be held at Koelnmesse in Cologne, Germany, from November 9–11, 2026.
Official website: https://informaconnect.com/bioeurope/
Representatives from Hokkaido University will present a broad portfolio of research achievements and innovative technologies in the fields of drug discovery, drug delivery, oncology, immunology, regenerative medicine, diagnostics, and medical devices.
Through BIO-Europe 2026, Hokkaido University seeks to further promote international research exchange and contribute to the advancement of biopharmaceutical science and innovation.
1. Neurology, Ophthalmology & Nerve Regeneration
1. GFRα1: A First-in-Class Lead for Functional CNS and PNS Nerve Regeneration
2. p3-Alcβ9-19: A Primate-Validated, Brain-Penetrant Mitochondrial Activator for AD
3. Targeted RNA Chaperones: A Precise Mechanism to Protect Motor Neurons in ALS
4. NET Inhibitors: Accelerating Acute Nerve Repair via the MIF/CXCR4 Axis
29. BDNF-Inducing Peptides: A Neuroprotective Approach for Glaucoma Treatment, Complementing IOP-lowering therapy
30. Topical Tramadol Eye Drops for Blepharospasm and Ocular Hypersensitivity
2. p3-Alcβ9-19: A Primate-Validated, Brain-Penetrant Mitochondrial Activator for AD
3. Targeted RNA Chaperones: A Precise Mechanism to Protect Motor Neurons in ALS
4. NET Inhibitors: Accelerating Acute Nerve Repair via the MIF/CXCR4 Axis
29. BDNF-Inducing Peptides: A Neuroprotective Approach for Glaucoma Treatment, Complementing IOP-lowering therapy
30. Topical Tramadol Eye Drops for Blepharospasm and Ocular Hypersensitivity
2. Drug Delivery, RNA & Gene Therapy
5. HSC-Targeted LNPs: A Precision Delivery Platform for Reversing Hepatic Fibrosis
6. Spleen-Specific LNPs: Optimized Dendritic Cell Delivery for Next-Gen Vaccines
7. Helper Lipids: A Potency-Boosting Solution for Enhanced Endosomal Escape
8. Novel ζ-Lipids for Cas9 RNP Delivery: 98% Gene Knockout in vivo
9. NK Cell-Specific LNPs: Scalable Genetic Modification for Cold Tumor Therapy
10. Novel Cationic Lipids for Extrahepatic Delivery
11. Lung-Targeted LNP Anti-Inflammatory Drug Delivery Technology — Efficacy Demonstrated in Severe
COVID-19 Pneumonia Models
24. srRNA: A Stable, Vector-Based Alternative for Exon-Skipping Therapies
25. MITO-Porter & CRISPR/Cas9: An Advanced Platform for Mitochondrial Gene Editing
6. Spleen-Specific LNPs: Optimized Dendritic Cell Delivery for Next-Gen Vaccines
7. Helper Lipids: A Potency-Boosting Solution for Enhanced Endosomal Escape
8. Novel ζ-Lipids for Cas9 RNP Delivery: 98% Gene Knockout in vivo
9. NK Cell-Specific LNPs: Scalable Genetic Modification for Cold Tumor Therapy
10. Novel Cationic Lipids for Extrahepatic Delivery
11. Lung-Targeted LNP Anti-Inflammatory Drug Delivery Technology — Efficacy Demonstrated in Severe
COVID-19 Pneumonia Models
24. srRNA: A Stable, Vector-Based Alternative for Exon-Skipping Therapies
25. MITO-Porter & CRISPR/Cas9: An Advanced Platform for Mitochondrial Gene Editing
3. Oncology & Cancer Therapeutics
12. PIECE Platform Technology targeting Intracellular IL-6 for Tumor Therapeutics
13. Anti-IL-34 mAbs: Strategic Add-ons to Overcome Therapeutic Resistance
14. DCA-Micelles: A Precision Metabolic Radiosensitizer for Local Tumor Control
15. Drug Discovery Targeting the BATF3/IRF4 Axis Enabling Indication Expansion Beyond ATLL
16. A Novel Therapeutic Strategy for HCC Targeting Tumor Metabolic Transporters
17. Retinoid Pathway-Targeted Therapy for Synovial Sarcoma and Soft Tissue Sarcomas
18. Dual MCT1/MCT4 Inhibition Strategy for Hypoxia-Resistant Hepatocellular Carcinoma
20. Next-Gen STING Agonists: Converting Cold Tumors via Potent Systemic Activation
13. Anti-IL-34 mAbs: Strategic Add-ons to Overcome Therapeutic Resistance
14. DCA-Micelles: A Precision Metabolic Radiosensitizer for Local Tumor Control
15. Drug Discovery Targeting the BATF3/IRF4 Axis Enabling Indication Expansion Beyond ATLL
16. A Novel Therapeutic Strategy for HCC Targeting Tumor Metabolic Transporters
17. Retinoid Pathway-Targeted Therapy for Synovial Sarcoma and Soft Tissue Sarcomas
18. Dual MCT1/MCT4 Inhibition Strategy for Hypoxia-Resistant Hepatocellular Carcinoma
20. Next-Gen STING Agonists: Converting Cold Tumors via Potent Systemic Activation
4. Immunology, Inflammation & Other Therapeutics
19. Epigenetic Modulator for Refractory GVHD and IBD
21. STAP-1 Peptides: Selective T-Cell Modulation for Precision Autoimmune Therapy
22. Restoring NET Degradation in ANCA Vasculitis
23. Meflin: A Novel Biomarker and Therapeutic Target for Systemic Inflammation
26. IL-34-Induced Macrophages: Autologous Cell Therapy for Advanced Liver Cirrhosis
27. Resolvin E3 Indoles: A Pro-Resolving Approach for Insulin Resistance
28. Syk Inhibitors: A Safety Bridge for Post-Denosumab Transition in Osteoporosis
31. Selective Senolytics: Removing Senescent Cells to Reverse UV-Induced Skin Aging
21. STAP-1 Peptides: Selective T-Cell Modulation for Precision Autoimmune Therapy
22. Restoring NET Degradation in ANCA Vasculitis
23. Meflin: A Novel Biomarker and Therapeutic Target for Systemic Inflammation
26. IL-34-Induced Macrophages: Autologous Cell Therapy for Advanced Liver Cirrhosis
27. Resolvin E3 Indoles: A Pro-Resolving Approach for Insulin Resistance
28. Syk Inhibitors: A Safety Bridge for Post-Denosumab Transition in Osteoporosis
31. Selective Senolytics: Removing Senescent Cells to Reverse UV-Induced Skin Aging
5. Infectious Diseases & Antimicrobial Therapeutics
32. Neutralizing mAbs for Marburg Virus: High-Potency Outbreak Control Tools
33. Universal Pan-Species Ebola Antibodies: A Cross-Neutralizing Therapeutic Lead
34. Nemuri-Derived Peptides: A New Line of Defense Against MDR Bacterial Pathogens
35. 2-thiouridine (s2U): A Broad-Spectrum Antiviral for Positive-Strand RNA Viruses
33. Universal Pan-Species Ebola Antibodies: A Cross-Neutralizing Therapeutic Lead
34. Nemuri-Derived Peptides: A New Line of Defense Against MDR Bacterial Pathogens
35. 2-thiouridine (s2U): A Broad-Spectrum Antiviral for Positive-Strand RNA Viruses
6. Diagnostics, Research Technologies & Medical Devices
36. Bioluminescent BLI Mice: Real-Time evaluation for Reproductive Toxicity
37. Enhanced Mammalian Cell Vectors: High-Yield Production of Bio-Active Proteins
38. IgA N-Glycan Markers: A Non-Invasive Diagnostic Tool for MASH Fibrosis Stages
39. HD5 Diagnostic Kits: Precision Monitoring for Intestinal Health and Microbiome
40. Micro-Scale SAR Platform: Rapid Structure-Optimization for Peptide Leads
41. Nonribosomal Peptide Cyclases: A High-Throughput Engine for Cyclic Peptide Discovery
42. Portable Parasite NGS: A Field-Ready Comprehensive Detection System
43. Ultra-Sensitive Immunoassay Platform Using Advanced Optical Sensing
44. Attachment for Microscope Objective Lenses and Microscope
45. Non-Invasive taVNS Device: A Neuromodulation Strategy for Interstitial Pneumonia
46. Biomimetic Artificial Cartilage Implant for Durable Joint Repair
47. Cation-π Polymer Embolic Agent: Safe, Injectable, and Stable Vessel Occlusion
37. Enhanced Mammalian Cell Vectors: High-Yield Production of Bio-Active Proteins
38. IgA N-Glycan Markers: A Non-Invasive Diagnostic Tool for MASH Fibrosis Stages
39. HD5 Diagnostic Kits: Precision Monitoring for Intestinal Health and Microbiome
40. Micro-Scale SAR Platform: Rapid Structure-Optimization for Peptide Leads
41. Nonribosomal Peptide Cyclases: A High-Throughput Engine for Cyclic Peptide Discovery
42. Portable Parasite NGS: A Field-Ready Comprehensive Detection System
43. Ultra-Sensitive Immunoassay Platform Using Advanced Optical Sensing
44. Attachment for Microscope Objective Lenses and Microscope
45. Non-Invasive taVNS Device: A Neuromodulation Strategy for Interstitial Pneumonia
46. Biomimetic Artificial Cartilage Implant for Durable Joint Repair
47. Cation-π Polymer Embolic Agent: Safe, Injectable, and Stable Vessel Occlusion